BSP16
Based on 1 Customer Validation
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 can selectively stimulate the STING pathway. BSP16 can be used for the research of cancer.
For research use only. We do not sell to patients.
- Purity: 98.3%
- CAS No.: 2727249-47-8
- Formula: C16H18O5Se
- Molecular Weight:369.27
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
IC50 for STING: 9.24 μM (ISG-THP1 cells); 5.71 μM (ISGRAW264.7 cells)[1]
BSP16 (0.1-100 μM) can selectively stimulate the STING pathway in ISG-THP1 and ISGRAW264.7 cells with EC50 values of 9.24 and 5.71 μM, respectively[1].
BSP16 (10, 25, 50 μM; 1, 3, 6 h) strongly activates STING signaling in human and mouse cells and binds STING as a homodimer[1].
BSP16 exhibits a promising absorption, distribution, metabolism, excretion and toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:ISG-THP1 cells
-
Concentration:10, 25, 50 μM
-
Incubation Time:1, 3, 6 h
-
Result:Robustly induced mRNA expression of target genes IFNβ, CXCL10, and IL6 in response to STING activation, in a time and concentration-dependent manner in ISGTHP1 cells.
-
Cell Line:ISG-THP1 cells
-
Concentration:10, 25, 50 μM
-
Incubation Time:1, 3, 6 h
-
Result:Rapidly increased the phosphorylation of TBK1 and IRF3 in a concentration-dependent manner.
BSP16 (oral, 15 and 30 mg/kg, q3d; oral, 20 mg/kg, q5d) induces tumor regression and durable antitumor immunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MC38 (colon carcinoma) syngeneic tumor model[1]
-
Dosage:15, 30 mg/kg
-
Administration:oral, q3d
-
Result:Exhibited tolerated and excellent antitumor efficacy, experienced complete tumor regression (CR) after day 21.
Resulted in robust induction of IFNB and IL6 (30 mg/kg).
-
Animal Model:CT26 (colon carcinoma) tumor model[1]
-
Dosage:20 mg/kg
-
Administration:oral, q5d
-
Result:Exhibited tolerated and induced tumor regression in all treated mice within 30 days.
Led to a substantial elevation of IFNB in the plasma in CT26 bearing mice.
-
Animal Model:Rats[1]
-
Dosage:5 mg/kg, 50 mg/kg
-
Administration:oral and i.v
-
Result:
compd. adm. Cmax(μg/mL) AUG0-∞(h*μg/mL) t1/2(h) Vss(L/kg) CL(L/h/kg) F(%) BSP16 po(50 mg/kg) 58.2 315.9 1.60 0.38 0.16 107 iv(5 mg/kg) 29.4 1.04 0.26 0.17
Chemical Information
-
CAS No. 2727249-47-8
-
Appearance Solid
-
Molecular Weight 369.27
-
Formula C16H18O5Se
-
Color Light yellow to yellow
-
SMILES
OC([C@H](CC)CC(C1=CC2=CC(OC)=C(OC)C=C2[Se]1)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)